Skip to main content
Trending
Corporate earningsAi infrastructureEnergy marketsElection litigationAviation safetyCrypto securityAi governanceEnterprise aiPlatform liabilityAvian influenzaClinical trialsFederal debtPresidential runoffRpg developmentSpace debrisAir defenseAutonomous vehiclesBudget crisisBug bountiesEnergy m&aForeign investmentFranchise restructuringGene therapyPandemic treatyTranslation pathwaysUn peacekeepingWeapons testingWeight-space programmingAi copyright lawArchaeological toxicology

full timeline

Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS

Pooled Phase 3 results presented at the MSToronto2026 meeting demonstrate that the investigational BTK inhibitor fenebrutinib significantly reduces imaging markers of chronic brain inflammation in both relapsing and primary progressive multiple sclerosis. The findings mark the first prospective demonstration of a therapeutic effect on chronic active lesions in late-stage MS trials.

Factlen Newsroom· Updated

Follow Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS in the Factlen app and get an alert when there is news. Get the app

Illustration: Phase 3 trial data indicates that fenebrutinib significantly reduces the volume of slowly expanding lesions visible on MRI scans.From: Phase 3 Trial Data Shows Fenebrutinib Curbs Chronic Active Lesions in Multiple Sclerosis

Share this story

Key numbers

12%
Reduction in risk of disability progression vs. Ocrevus (PPMS)
26%
Reduced risk of worsening upper limb function (PPMS)
51–59%
Reduction in annualized relapse rate vs. teriflunomide (RMS)
24 weeks
Time to initial separation of disability progression curves
13.3%
Rate of transient liver enzyme elevations on fenebrutinib

From: Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS

Charts, maps and images

Phase III trial data shows fenebrutinib outperformed standard-of-care treatments in both progressive and relapsing MS.From: Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS ·
In the FENtrepid trial, patients taking fenebrutinib showed a lower risk of disability progression starting as early as 24 weeks.From: Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS ·
Unlike older biologic therapies, fenebrutinib is a small molecule designed to penetrate the central nervous system.From: Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS ·
Illustration: Fenebrutinib is designed to cross the blood-brain barrier and inhibit the immune cells responsible for chronic tissue damage.From: Phase 3 Trial Data Shows Fenebrutinib Curbs Chronic Active Lesions in Multiple Sclerosis ·
Illustration: If approved by the FDA, fenebrutinib would become the first highly effective oral treatment for primary progressive multiple sclerosis.From: Phase 3 Trial Data Shows Fenebrutinib Curbs Chronic Active Lesions in Multiple Sclerosis ·
Illustration: The multiple sclerosis community is closely watching the FDA's priority review of the novel oral therapy.From: Phase 3 Trial Data Shows Fenebrutinib Curbs Chronic Active Lesions in Multiple Sclerosis ·
Show 1 more
Fenebrutinib reduced the risk of worsening upper limb function, a critical metric for maintaining daily independence.From: Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS ·

Timeline

October 2026

  1. Phase 3 Trial Data Shows Fenebrutinib Curbs Chronic Active Lesions in Multiple Sclerosis

August 2026

  1. Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS